negative regulation of glomerulus development
Definition
Target type: biologicalprocess
Any process that decreases the rate, frequency or extent of glomerulus development, the progression of the glomerulus over time from its initial formation until its mature state. The glomerulus is a capillary tuft surrounded by Bowman's capsule in nephrons of the vertebrate kidney. [GOC:dph, GOC:tb, GOC:yaf]
Negative regulation of glomerulus development is a complex biological process that ensures the proper formation and function of the glomerulus, the filtering unit of the kidney. This process involves a intricate interplay of signaling pathways, transcription factors, and growth factors, which act in a coordinated manner to fine-tune the development of the glomerular structure.
One of the key mechanisms involved is the precise control of cell proliferation and differentiation within the glomerulus. This is achieved through the actions of various growth factors, such as VEGF (vascular endothelial growth factor) and PDGF (platelet-derived growth factor), which promote the development of the glomerular capillaries and mesangial cells, respectively. However, uncontrolled growth can lead to abnormal glomerular development. Therefore, negative regulators are crucial to ensure that these processes are tightly controlled.
Several signaling pathways play a role in negative regulation of glomerulus development. The TGF-beta (transforming growth factor-beta) pathway is a prominent player, known for its role in inhibiting proliferation and promoting extracellular matrix production. Activation of this pathway can suppress the development of glomerular capillaries and mesangial cells, thus limiting excessive growth.
Other pathways, such as the Wnt and Notch pathways, also contribute to the negative regulation of glomerulus development. Wnt signaling can inhibit proliferation and promote differentiation, while Notch signaling can control the branching of the glomerular capillaries. These pathways work in concert to fine-tune the development of the glomerular structure.
In addition to these signaling pathways, transcription factors also play a vital role in regulating gene expression during glomerular development. For example, the transcription factor Pax2 is involved in the development of the glomerular tuft and podocytes, and its dysregulation can lead to abnormal glomerulus formation.
Furthermore, negative regulation of glomerulus development involves the precise control of cell adhesion and migration. Integrins and other cell adhesion molecules play a crucial role in guiding the movement of cells and the formation of the glomerular filtration barrier. Disruptions in these processes can lead to defects in the glomerular structure and function.
In conclusion, negative regulation of glomerulus development is a tightly controlled process involving a complex interplay of signaling pathways, transcription factors, and growth factors. This intricate network ensures the proper formation and function of the glomerulus, preventing uncontrolled growth and maintaining the delicate balance of the kidney filtration system.'
"
Proteins (1)
| Protein | Definition | Taxonomy |
|---|---|---|
| Bone morphogenetic protein 4 | A bone morphogenetic protein 4 that is encoded in the genome of human. [PRO:CNA, UniProtKB:P12644] | Homo sapiens (human) |
Compounds (3)
| Compound | Definition | Classes | Roles |
|---|---|---|---|
| dorsomorphin | dorsomorphin : A pyrazolopyrimidine that is pyrazolo[1,5-a]pyrimidine which is substituted at positions 3 and 6 by pyridin-4-yl and p-[2-(piperidin-1-yl)ethoxy]phenyl groups, respectively. It is a potent, selective, reversible, and ATP-competitive inhibitor of AMPK (AMP-activated protein kinase, EC 2.7.11.31) and a selective inhibitor of bone morphogenetic protein (BMP) signaling. dorsomorphin: an AMPK inhibitor | aromatic ether; piperidines; pyrazolopyrimidine; pyridines | bone morphogenetic protein receptor antagonist; EC 2.7.11.31 {[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase} inhibitor |
| ldn 193189 | LDN 193189: inhibits bone morphogenetic protein signaling | pyrimidines | |
| ml347 | ML347: an ALK2 inhibitor; structure in first source |